Quantinno Capital Management LP increased its position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 205.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 9,991 shares of the medical research company's stock after purchasing an additional 6,720 shares during the period. Quantinno Capital Management LP's holdings in Exact Sciences were worth $561,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Capital World Investors lifted its stake in Exact Sciences by 10.7% in the fourth quarter. Capital World Investors now owns 17,537,617 shares of the medical research company's stock valued at $985,439,000 after buying an additional 1,696,321 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Exact Sciences by 74.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,760,241 shares of the medical research company's stock valued at $323,669,000 after purchasing an additional 2,462,165 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in Exact Sciences by 25.8% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,269,823 shares of the medical research company's stock worth $239,922,000 after purchasing an additional 876,985 shares during the period. Geode Capital Management LLC boosted its stake in Exact Sciences by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 3,122,798 shares of the medical research company's stock worth $175,165,000 after purchasing an additional 16,828 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in Exact Sciences by 3.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,330,939 shares of the medical research company's stock worth $74,785,000 after purchasing an additional 38,849 shares during the last quarter. 88.82% of the stock is owned by institutional investors and hedge funds.
Exact Sciences Price Performance
NASDAQ EXAS traded down $0.52 during mid-day trading on Friday, hitting $57.11. The stock had a trading volume of 309,199 shares, compared to its average volume of 2,535,239. The company has a 50 day simple moving average of $48.51 and a 200 day simple moving average of $51.99. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. The company has a market cap of $10.77 billion, a price-to-earnings ratio of -10.26 and a beta of 0.92. Exact Sciences Co. has a 52-week low of $39.97 and a 52-week high of $72.83.
Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.16. The business had revenue of $706.79 million during the quarter, compared to the consensus estimate of $688.58 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The business's revenue was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.60) EPS. Equities analysts forecast that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of brokerages have recently commented on EXAS. Royal Bank of Canada increased their target price on shares of Exact Sciences from $52.00 to $54.00 and gave the stock a "sector perform" rating in a research note on Friday, May 2nd. Guggenheim reaffirmed a "buy" rating and set a $60.00 price objective on shares of Exact Sciences in a research report on Friday, April 11th. Piper Sandler lowered their target price on Exact Sciences from $75.00 to $70.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Robert W. Baird upped their price target on Exact Sciences from $69.00 to $72.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. Finally, Evercore ISI lifted their price objective on shares of Exact Sciences from $60.00 to $66.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Two analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $70.90.
Check Out Our Latest Stock Analysis on Exact Sciences
Exact Sciences Company Profile
(
Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
See Also
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
